Lebrikizumab Dosed Every 8 Weeks as Maintenance Provides Long-Lasting Response in Patients with Moderate-to-Severe Atopic Dermatitis. J of Skin [Internet]. 2025 Nov. 10 [cited 2026 May 2];9(6):s601. Available from: https://skin.dermsquared.com/skin/article/view/3802